Literature DB >> 23600768

Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas.

Steven M Strasberg1, Feng Gao, Dominic Sanford, David C Linehan, William G Hawkins, Ryan Fields, Danielle H Carpenter, Elizabeth M Brunt, Carolyn Phillips.   

Abstract

OBJECTIVES: Jaundice impairs cellular immunity, an important defence against the dissemination of cancer. Jaundice is a common mode of presentation in pancreatic head adenocarcinoma. The purpose of this study was to determine whether there is an association between preoperative jaundice and survival in patients who have undergone resection of such tumours.
METHODS: Thirty possible survival risk factors were evaluated in a database of over 400 resected patients. Univariate analysis was used to determine odds ratio for death. All factors for which a P-value of <0.30 was obtained were entered into a multivariate analysis using the Cox model with backward selection.
RESULTS: Preoperative jaundice, age, positive node status, poor differentiation and lymphatic invasion were significant indicators of poor outcome in multivariate analysis. Absence of jaundice was a highly favourable prognostic factor. Interaction emerged between jaundice and nodal status. The benefit conferred by the absence of jaundice was restricted to patients in whom negative node status was present. Five-year overall survival in this group was 66%. Jaundiced patients who underwent preoperative stenting had a survival advantage.
CONCLUSIONS: Preoperative jaundice is a negative risk factor in adenocarcinoma of the pancreas. Additional studies are required to determine the exact mechanism for this effect.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2013        PMID: 23600768      PMCID: PMC3921010          DOI: 10.1111/hpb.12094

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  15 in total

Review 1.  Compromise of immune function in obstructive jaundice.

Authors:  László Nehéz; Roland Andersson
Journal:  Eur J Surg       Date:  2002

2.  Phagocytosis and production of H2O2 by human peripheral blood mononuclear cells from patients with obstructive jaundice.

Authors:  Marisa Treglia-Dal Lago; Jose Jukemura; Marcel Cerqueira Cesar Machado; Jose Eduardo Monteiro da Cunha; Jose Alexandre Marzagão Barbuto
Journal:  Pancreatology       Date:  2006-04-19       Impact factor: 3.996

3.  Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients.

Authors:  K F D Kuhlmann; S M M de Castro; J G Wesseling; F J W ten Kate; G J A Offerhaus; O R C Busch; T M van Gulik; H Obertop; D J Gouma
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

4.  Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage.

Authors:  Wietse J Eshuis; Niels A van der Gaag; Erik A J Rauws; Casper H J van Eijck; Marco J Bruno; Ernst J Kuipers; Peter P Coene; Frank J G M Kubben; Josephus J G M Gerritsen; Jan Willem Greve; Michael F Gerhards; Ignace H J T de Hingh; Jean H Klinkenbijl; C Y Nio; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Patrick M M Bossuyt; Dirk J Gouma
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

5.  Preoperative resolution of jaundice following biliary stenting predicts more favourable early survival in resected pancreatic ductal adenocarcinoma.

Authors:  Richard A Smith; K Dajani; S Dodd; P Whelan; M Raraty; R Sutton; F Campbell; J P Neoptolemos; P Ghaneh
Journal:  Ann Surg Oncol       Date:  2008-09-12       Impact factor: 5.344

6.  A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators.

Authors:  Richard Kim; Raymond Tsao; Ann Tan; Mike Byrne; Khaldoun Almhanna; Aleksander Lazaryan; Paul Elson; Robert J Pelley
Journal:  J Gastrointest Surg       Date:  2010-05-06       Impact factor: 3.452

7.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

8.  Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis.

Authors:  Steven C Katz; Kristin Ryan; Naseem Ahmed; George Plitas; Umer I Chaudhry; T Peter Kingham; Seema Naheed; Cang Nguyen; Ponnandai Somasundar; N Joseph Espat; Richard P Junghans; Ronald P Dematteo
Journal:  J Immunol       Date:  2011-06-22       Impact factor: 5.422

9.  Pancreaticoduodenectomy: a 20-year experience in 516 patients.

Authors:  C Max Schmidt; Emilie S Powell; Constantin T Yiannoutsos; Thomas J Howard; Eric A Wiebke; Chad A Wiesenauer; Joel A Baumgardner; Oscar W Cummings; Lewis E Jacobson; Thomas A Broadie; David F Canal; Robert J Goulet; Eardie A Curie; Higinia Cardenes; John M Watkins; Patrick J Loehrer; Keith D Lillemoe; James A Madura
Journal:  Arch Surg       Date:  2004-07

10.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

View more
  20 in total

Review 1.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Current status of preoperative biliary drainage.

Authors:  Junko Umeda; Takao Itoi
Journal:  J Gastroenterol       Date:  2015-07-03       Impact factor: 7.527

3.  The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy.

Authors:  Daisaku Yamada; Hidetoshi Eguchi; Tadafumi Asaoka; Hideo Tomihara; Takehiro Noda; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2017-04-18       Impact factor: 2.549

4.  Long-Term Endocrine and Exocrine Insufficiency After Pancreatectomy.

Authors:  Jiro Kusakabe; Blaire Anderson; Jingxia Liu; Gregory A Williams; William C Chapman; Majella M B Doyle; Adeel S Khan; Dominic E Sanford; Chet W Hammill; Steven M Strasberg; William G Hawkins; Ryan C Fields
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

5.  Jaundice in resected pancreatic cancer patients.

Authors:  Fenja M Feld; Jochen K Lennerz
Journal:  HPB (Oxford)       Date:  2014-02       Impact factor: 3.647

Review 6.  Malignant biliary obstruction: From palliation to treatment.

Authors:  Brian R Boulay; Aleksandr Birg
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

7.  Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Bart M G Baekelandt; Marianne J Hjermstad; Tom Nordby; Morten W Fagerland; Elin H Kure; Turid Heiberg; Trond Buanes; Knut J Labori
Journal:  HPB (Oxford)       Date:  2015-11-19       Impact factor: 3.647

8.  Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?

Authors:  Thuy B Tran; Jeffrey A Norton; Cecilia G Ethun; Timothy M Pawlik; Stefan Buettner; Carl Schmidt; Eliza W Beal; William G Hawkins; Ryan C Fields; Bradley A Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Kamran Idrees; Chelsea A Isom; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; George A Poultsides
Journal:  J Gastrointest Surg       Date:  2017-05-11       Impact factor: 3.452

9.  Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach.

Authors:  Brent T Xia; David A Habib; Vikrom K Dhar; Nick C Levinsky; Young Kim; Dennis J Hanseman; Jeffrey M Sutton; Gregory C Wilson; Milton Smith; Kyuran Ann Choe; Jeffrey J Sussman; Syed A Ahmad; Daniel E Abbott
Journal:  Ann Surg Oncol       Date:  2016-07-26       Impact factor: 5.344

10.  The prognostic value of Cyclin B1 in pancreatic cancer.

Authors:  Li Zhou; Jian Li; Yu-Pei Zhao; Quan-Cai Cui; Wei-Xun Zhou; Jun-Chao Guo; Lei You; Wen-Ming Wu; Tai-Ping Zhang
Journal:  Med Oncol       Date:  2014-08-09       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.